OINDP research and development specialist Nanopharm has partnered with Leyden Labs for development of Leyden Labs antiviral nasal spray candidates, the companies have announced. Nanopharm, which was acquired by Aptar Pharma in 2019, will develop a liquid nasal formulation in preparation for Phase 1 trials and may evaluate a powder formulation as well. In March 2021, Leyden Labs announced that it had raised €40 Million for development of intranasal products targeting respiratory viruses.
Nanopharm CEO Jag Shur said, “Leyden Labs is taking a really exciting approach to finding solutions for the broad-spectrum prophylactic protection against respiratory viruses. Their platform and portfolio of product candidates show real promise, and we are proud to be a part of its development to fast-track its approach towards the clinic, utilizing our fundamental scientific understanding of OINDPs and our knowledge of how to expedite product development.”
Aptar Pharma VP of Analytical, Regulatory and Scientific Affairs Guillaume Brouet, commented, “We are pleased to support Leyden Labs in this important development, which reinforces the Aptar Pharma Services mission to further help customers during their entire drug development journey and deliver them a complete solution.”
Leyden Labs CEO Koenraad Wiedhaup said, “Nanopharm’s team has the world-leading expertise needed to understand and develop safe, effective formulations targeting respiratory viruses. This partnership enables us to efficiently bring our product candidates to people in need of better protection against new pandemics and seasonal outbreaks like those caused by influenza and coronaviruses. We look forward to continuing to work with Nanopharm in the future to further develop additional product candidates and swiftly advance them into the clinic.”
Read the Nanopharm press release.
